Welcome to our dedicated page for Voyager Therapeutics SEC filings (Ticker: VYGR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Voyager Therapeutics, Inc. (Nasdaq: VYGR) SEC filings page on Stock Titan brings together the company’s public regulatory disclosures, including current reports on Form 8-K that furnish financial results, corporate updates, and investor presentations. As a Delaware-incorporated public company with common stock listed on the Nasdaq Global Select Market, Voyager files with the U.S. Securities and Exchange Commission to report material information related to its biotechnology business focused on neurological diseases.
Through these filings, readers can access details on Voyager’s collaboration revenue, research and development and general and administrative expenses, net loss, and cash, cash equivalents, and marketable securities. The company’s 8-K filings often attach press releases that describe quarterly financial and operating results, cash runway expectations, and progress across its pipeline, including Alzheimer’s disease programs such as the anti-tau antibody VY7523 and tau silencing gene therapy VY1706, as well as partnered gene therapy programs with Neurocrine Biosciences and collaborations with Novartis and other partners.
Voyager’s filings also reference its TRACER™ AAV capsid discovery platform, next-generation capsids designed for blood-brain barrier penetration, and collaborations such as the small molecule discovery and license option agreement with Transition Bio targeting TDP-43 in ALS and frontotemporal dementia. Forward-looking statements and risk disclosures in these documents outline uncertainties related to regulatory decisions, clinical development, collaboration milestones, intellectual property, and the company’s ability to fund operations.
On Stock Titan, SEC documents are paired with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly identify major financial metrics, pipeline updates, and collaboration terms. Users can follow new 8-Ks and other SEC reports in real time, review historical filings for context on Voyager’s evolution, and connect these disclosures to the company’s news flow and stock performance.
Voyager Therapeutics, Inc. President and CEO Alfred Sandrock reported an open-market sale of 11,511 shares of common stock at a weighted average price of $3.87 per share. The transaction occurred under a durable automatic sale instruction to cover tax withholding on restricted stock units that vested on April 1, 2026.
The filing notes the sale was not a discretionary trade by Sandrock. Following this sell-to-cover transaction, he directly holds 472,549 shares of Voyager Therapeutics common stock.
Shiferman Gregory L. reported acquisition or exercise transactions in this Form 4 filing.
Voyager Therapeutics, Inc. granted 50,000 restricted stock units (RSUs) to SVP and General Counsel Gregory L. Shiferman as equity compensation. Each RSU represents one share of common stock upon vesting.
The award was granted on April 1, 2026 under the Voyager Therapeutics, Inc. 2025 Stock Incentive Plan. The RSUs vest over three years: one-third on the first anniversary of the grant date and one-third on each of the next two anniversaries, contingent on his continued service. After this grant, he holds 50,000 shares/RSUs directly.
Issuer submitted a Form 144 notice listing 11,511 shares of Common stock associated with Restricted Stock Vesting and compensation, with an execution date noted as 04/01/2026. The filing also lists three recent sales by Alfred W. Sandrock Jr. on 02/10/2026, 02/18/2026, and 02/24/2026 for 12,192, 11,732, and 14,197 shares respectively.
Voyager Therapeutics Inc Schedule 13G/A amendment shows The Vanguard Group reports 0% beneficial ownership of Voyager common stock, with 0 shares reported. The filing notes an internal realignment on January 12, 2026, after which certain Vanguard subsidiaries report disaggregated ownership separately in reliance on SEC Release No. 34-39538. The amendment is signed by Ashley Grim on 03/27/2026.
Voyager Therapeutics, Inc. reported fourth quarter and full year 2025 financial and operating results, highlighting pipeline progress in Alzheimer’s disease, intravenous gene therapies, and its Voyager NeuroShuttle™ platform. Collaboration revenue for 2025 was $40.4 million, down from $80.0 million in 2024, while net loss widened to $119.7 million from $65.0 million.
The company ended 2025 with $201.7 million in cash, cash equivalents, and marketable securities and expects this to fund operations into 2028, assuming planned expenses and anticipated collaboration reimbursements and interest income. Management also notes potential additional non-dilutive development milestones of up to $2.4 billion under existing collaborations.
Voyager Therapeutics, Inc. files its annual report describing a genetics-driven pipeline targeting neurological diseases using AAV gene therapy and a non-viral NeuroShuttle platform. Programs focus on Alzheimer’s, Friedreich’s ataxia, Parkinson’s, Gaucher disease, Huntington’s and other CNS conditions, combining wholly owned assets with major pharma collaborations.
The company highlights Alzheimer’s candidates VY1706, a tau-silencing gene therapy expected to enter clinical testing in 2026, and VY7523, an anti-tau antibody now in a multiple-dose Phase 1 trial. Voyager reports more than $500.0 million in aggregate non-dilutive funding from partners and potential future milestones of up to $6.8 billion, alongside royalties, across Novartis, Neurocrine, Alexion/AstraZeneca and Transition Bio deals.
As of June 30, 2025, the aggregate market value of common stock held by non‑affiliates was approximately $144.2 million, and there were 59,599,375 common shares outstanding as of March 2, 2026. The filing also outlines extensive intellectual property around TRACER capsids, tau therapies, GBA1, frataxin and Huntington’s disease.
Voyager Therapeutics COO & CBO Robin Swartz reported an automatic tax-related sale of 6,458 common shares. On February 24, 2026, shares were sold in an open-market transaction at a weighted average price of $3.77 per share.
The sale was executed under a durable automatic sale instruction adopted on May 12, 2025 to cover tax withholding obligations from restricted stock units that vested on February 21, 2026, and is described as non-discretionary. After this sale, Swartz directly held 199,738 Voyager Therapeutics shares.
Voyager Therapeutics, Inc. director and President & CEO Alfred Sandrock reported an open-market sale of common stock tied to tax withholding. He sold 14,197 shares of common stock at a weighted average price of $3.79 per share in transactions on February 24, 2026.
The sale was executed under a durable automatic sale instruction adopted on May 12, 2025 to satisfy tax withholding obligations arising from the vesting of restricted stock units on February 21, 2026, and is described as not a discretionary trade. Following these transactions, Sandrock directly holds 484,060 shares of Voyager Therapeutics common stock.
Voyager Therapeutics, Inc. Chief Financial Officer Nathan D. Jorgensen reported an open-market sale of 4,668 shares of common stock at a weighted average price of $3.77 per share. After this non-discretionary sell-to-cover tax transaction, he holds 151,416 shares directly.
Voyager Therapeutics’ Chief Scientific Officer, Carter Todd Alfred, reported an automatic sale of 4,174 shares of common stock at a weighted average price of $3.76 per share.
The shares were sold under a pre-set instruction to cover tax withholding tied to restricted stock units vesting on February 21, 2026, and he continues to hold 145,718 shares directly.